1 | predicts the probability of | | | | | | | 6 | 0.39% |
2 | for patients with type | | | | | | | 6 | 0.39% |
3 | patients with type 2 | | | | | | | 6 | 0.39% |
4 | for patients immediately following | | | | | | | 4 | 0.26% |
5 | with type 2 diabetes | | | | | | | 4 | 0.26% |
6 | mortality for patients with | | | | | | | 4 | 0.26% |
7 | for patients eligible for | | | | | | | 3 | 0.20% |
8 | cancer screening with psa | | | | | | | 3 | 0.20% |
9 | screening with psa and | | | | | | | 3 | 0.20% |
10 | with psa and dre | | | | | | | 3 | 0.20% |
11 | undergoing prostate cancer screening | | | | | | | 3 | 0.20% |
12 | for patients with a | | | | | | | 3 | 0.20% |
13 | prostate cancer screening with | | | | | | | 3 | 0.20% |
14 | and sleeve gastrectomy predicts | | | | | | | 2 | 0.13% |
15 | covid19 predicts the probability | | | | | | | 2 | 0.13% |
16 | for patients immediately prior | | | | | | | 2 | 0.13% |
17 | patients who may benefit | | | | | | | 2 | 0.13% |
18 | who may benefit from | | | | | | | 2 | 0.13% |
19 | may benefit from more | | | | | | | 2 | 0.13% |
20 | biopsy risk calculator for | | | | | | | 2 | 0.13% |
21 | group biopsy risk calculator | | | | | | | 2 | 0.13% |
22 | based on clinical criteria | | | | | | | 2 | 0.13% |
23 | for covid19 predicts the | | | | | | | 2 | 0.13% |
24 | patients about to undergo | | | | | | | 2 | 0.13% |
25 | collaborative group biopsy risk | | | | | | | 2 | 0.13% |
26 | benefit from more aggressive | | | | | | | 2 | 0.13% |
27 | early postoperative diabetes remission | | | | | | | 2 | 0.13% |
28 | cancer for patients immediately | | | | | | | 2 | 0.13% |
29 | at 5 and 10year | | | | | | | 2 | 0.13% |
30 | of having prostate cancer | | | | | | | 2 | 0.13% |
31 | following radical prostatectomy predicts | | | | | | | 2 | 0.13% |
32 | for patients who are | | | | | | | 2 | 0.13% |
33 | sleeve gastrectomy predicts late | | | | | | | 2 | 0.13% |
34 | patients immediately prior to | | | | | | | 2 | 0.13% |
35 | patients recently testing positive | | | | | | | 2 | 0.13% |
36 | help identify patients who | | | | | | | 2 | 0.13% |
37 | bypass and sleeve gastrectomy | | | | | | | 2 | 0.13% |
38 | for patients with biochemical | | | | | | | 2 | 0.13% |
39 | predicts 30day probability of | | | | | | | 2 | 0.13% |
40 | colorectal cancer for patients | | | | | | | 2 | 0.13% |